AgingResearch.NewsJoin free

Inozyme Pharma

CompanyUnited States

Inozyme Pharma develops one asset, in phase 1 (INZ-701 in atp-binding cassette subfamily c member 6 deficiency). Mostly protein or enzyme acting on ENPP1; based in the United States.

1
Asset
Furthest stage
Phase 1
1
Trial
1
Signal

Pipeline

1

  • INZ-701

    Recombinant ENPP1 fusion protein increases extracellular pyrophosphate to inhibit pathological mineralization.

    Phase 1, Protein or enzyme, ENPP1, atp-binding cassette subfamily c member 6 deficiency, generalized arterial calcification of infancy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials1
  • Signals1
  • Similar companies1

Intelligence